NMT1 and neoplasm: This approach concentrates a pan-NMT inhibitor in tumor cells, resulting in robust tumor regression while maintaining a favorable safety profile and shows minimal off-target effects.This strategy combines the specificity of biologics with the robust intracellular activity of small molecules, potentially overcoming the distribution challenges faced by free drugs.